Vigilant Biosciences OncAlert Oral Cancer Product Line is Now Shipping

Posted: December 21, 2016
Edited by Dentaltown staff

FORT LAUDERDALE, Fla.—Vigilant Biosciences, a developer of solutions that aid in the early detection and intervention of cancer, recently announced that its OncAlert Oral Cancer product line is now shipping and available in select countries.

Additionally, the company announced the launch of its OncAlert Oral Cancer website, oncalert.com, an online resource for healthcare professionals interested in learning more about the product line.

The product line includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test. The tests are based on the commercially available technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels—markers clinically validated to be associated specifically with oral cancer. These tests are optimized for easy use by collecting samples via an oral saline rinse and measured either via a point-of-care lateral flow assay or a laboratory kit. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer, potentially even before visual or physical indicators.

"We are pleased to announce this major milestone with the shipping of our OncAlert Oral Cancer product line to our global distributors," said Matthew H.J. Kim, founder, chairman, and CEO of Vigilant Biosciences. "Globally, we have seen a rise in oral and oropharyngeal cancer rates in recent years, and new tools to aid in the diagnosis of oral cancer earlier—such as the OncAlert Oral Cancer line—are critical to reducing the high death rate associated with this disease. We look forward to working with all of our distribution and commercialization partners to provide innovative and cost-effective products that will result in earlier detection and intervention for patients at risk all over the world."

Vigilant Biosciences has previously announced multiple distribution agreements for its OncAlert Oral Cancer product line throughout Europe, Africa and Asia/Pacific and Latin America.
Views: 159
Sponsors
Townie Perks
Townie® Poll
Do you do more or less endo procedures since you started practicing?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450